{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T15:01:22Z","timestamp":1782226882163,"version":"3.54.5"},"reference-count":56,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T00:00:00Z","timestamp":1615766400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>COVID-19 caused by SARS-Cov-2 is a devastating infection in patients with hematological malignancies. In 2018, the Lebanese Society of Hematology and Blood Transfusion (LSHBT) updated the guidelines for the management of hematological malignancies in Lebanon. In 2019, it was followed by a second update. Given the rapidly changing evidence and general situation for COVID-19, the LSHBT established some recommendations and suggestions for the management of the patients with hematological malignancies taking into account the Lebanese condition, economic situation, and the facts that SARS-Cov-2 infection has apparently been devastating. In this article we present recommendations and proposals to reduce or to manage SARS-Cov-2 infection in the patients with myeloid and lymphoid hematological malignancies.<\/jats:p>","DOI":"10.3389\/fonc.2021.564383","type":"journal-article","created":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T05:59:11Z","timestamp":1615787951000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Changing Management of Hematological Malignancies With COVID-19: Statement and Recommendations of the Lebanese Society of Hematology and Blood Transfusion"],"prefix":"10.3389","volume":"11","author":[{"given":"Ahmad","family":"Ibrahim","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Noun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charbel","family":"Khalil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"Taher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,3,15]]},"reference":[{"key":"B1","unstructured":"Coronavirus Disease 20192020"},{"key":"B2","unstructured":"COVID-19 Coronavirus Lebanon Cases2020"},{"key":"B3","unstructured":"2020"},{"key":"B4","unstructured":"The European Hematology Association (EHA)Association (EHA) TEH. COVID-19 Recommendations2020"},{"key":"B5","unstructured":"COVID-19 Resources.2020"},{"key":"B6","unstructured":"ESMOCancer Patient Management During the COVID-19 Pandemic2020"},{"key":"B7","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1111\/bjh.16620","article-title":"Care of haematology patients in a COVID-19 epidemic","volume":"189","author":"Willan","year":"2020","journal-title":"Br J Haematol"},{"key":"B8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1111\/bjh.16597","article-title":"How do we plan hematopoietic cell transplant and cellular therapy with the looming COVID-19 threat?","volume":"189","author":"Dholaria","year":"2020","journal-title":"Br J Haematol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"424","DOI":"10.1182\/blood-2016-08-733196","article-title":"Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel","volume":"129","author":"D\u00f6hner","year":"2017","journal-title":"Blood"},{"key":"B10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1002\/ajh.25214","article-title":"Acute myeloid leukemia: 2019 update on risk-stratification and management","volume":"93","author":"Estey","year":"2018","journal-title":"Am J Hematol."},{"key":"B11","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1182\/blood-2015-08-604520","article-title":"An update of current treatments for adult acute myeloid leukemia","volume":"127","author":"Dombret","year":"2016","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood-2018-08-868752","article-title":"Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia","volume":"133","author":"DiNardo","year":"2019","journal-title":"Blood."},{"key":"B13","unstructured":"Venetoclax for AML: Changing the Treatment Paradigm2020"},{"key":"B14","doi-asserted-by":"publisher","first-page":"2795","DOI":"10.1038\/s41375-019-0612-8","article-title":"How we use venetoclax with hypomethylating agents for the treatment of newly diagnosed patients with acute myeloid leukemia","volume":"33","author":"Jonas","year":"2019","journal-title":"Leukemia."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1311","DOI":"10.1182\/bloodadvances.2019001267","article-title":"Outcomes of older patients with NPM1-mutated AML: current treatments and the promise of venetoclax-based regimens","volume":"4","author":"Lachowiez","year":"2020","journal-title":"Blood Adv"},{"key":"B16","doi-asserted-by":"publisher","first-page":"8265","DOI":"10.2147\/OTT.S150807","article-title":"The return of gemtuzumab ozogamicin: a humanized anti-CD33 monoclonal antibody\u2013drug conjugate for the treatment of newly diagnosed acute myeloid leukemia","volume":"11","author":"Egan","year":"2018","journal-title":"Onco Targets Ther"},{"key":"B17","doi-asserted-by":"publisher","first-page":"1553","DOI":"10.1038\/s41375-019-0697-0","article-title":"The clinical mutatome of core binding factor leukemia","volume":"34","author":"Opatz","year":"2020","journal-title":"Leukemia"},{"key":"B18","doi-asserted-by":"publisher","first-page":"9509","DOI":"10.1038\/s41598-017-10368-0","article-title":"Efficacy and safety of different doses of cytarabine in consolidation therapy for adult acute myeloid leukemia patients: a network meta-analysis","volume":"7","author":"Wu","year":"2017","journal-title":"Sci Rep"},{"key":"B19","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.3324\/haematol.2018.198614","article-title":"Arsenic trioxide is required in the treatment of newly diagnosed acute promyelocytic leukemia. Analysis of a randomized trial (APL 2006) by the French Belgian Swiss APL group","volume":"103","author":"Ad\u00e8s","year":"2018","journal-title":"Haematologica"},{"key":"B20","unstructured":"MD Anderson Cancer CenterHighlights in Myelodysplastic Syndromes from the 60th American Society of Hematology Annual Meeting: Commentary2020"},{"key":"B21","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in patients with lower-risk myelodysplastic syndromes","volume":"382","author":"Fenaux","year":"2020","journal-title":"N Engl J Med"},{"key":"B22","unstructured":"LeukemiaEuropean LeukemiaNet 2020 Recommendations for Treating Chronic Myeloid Leukemia2020"},{"key":"B23","doi-asserted-by":"publisher","first-page":"2001919","DOI":"10.1183\/13993003.01919-2020","article-title":"JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk","volume":"56","author":"Mehta","year":"2020","journal-title":"Eur Respir J."},{"key":"B24","doi-asserted-by":"publisher","first-page":"1186","DOI":"10.3389\/fonc.2019.01186","article-title":"Mechanisms underlying the anti-inflammatory and immunosuppressive activity of ruxolitinib","volume":"9","author":"Elli","year":"2019","journal-title":"Front Oncol"},{"key":"B25","unstructured":"Europe PMCOvercoming Treatment Challenges in Myelofibrosis and Polycythemia Vera: The Role of Ruxolitinib2020"},{"key":"B26","first-page":"70","volume-title":"NCCN Guidelines for Patients Myeloproliferative Neoplasms. Myeloproliferative Neoplasms","year":"2019"},{"key":"B27","first-page":"2606","article-title":"Expert U.S. panel develops NIH treatment guidelines for COVID-19","volume":"60","year":"2020","journal-title":"Natl Inst Health"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2606","DOI":"10.1080\/10428194.2019.1605071","article-title":"Recent advances in the treatment of acute lymphoblastic leukemia","volume":"60","author":"Rafei","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"B29","doi-asserted-by":"publisher","first-page":"2579","DOI":"10.1002\/cncr.32139","article-title":"Inotuzumab ozogamicin in combination with low-intensity chemotherapy (mini-HCVD) with or without blinatumomab versus standard intensive chemotherapy (HCVAD) as frontline therapy for older patients with Philadelphia chromosome-negative acute lymphoblastic leukemia: a propensity score analysis","volume":"125","author":"Jabbour","year":"2019","journal-title":"Cancer"},{"key":"B30","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1182\/blood-2018-08-832105","article-title":"How I treat Philadelphia chromosome\u2013positive acute lymphoblastic leukemia","volume":"133","author":"Ravandi","year":"2019","journal-title":"Blood"},{"key":"B31","doi-asserted-by":"publisher","first-page":"1266","DOI":"10.1002\/ajh.25595","article-title":"Chronic lymphocytic leukemia: 2020 update on diagnosis, risk stratification and treatment","volume":"94","author":"Hallek","year":"2019","journal-title":"Am J Hematol"},{"key":"B32","doi-asserted-by":"publisher","first-page":"2041","DOI":"10.1182\/blood.2019002729","article-title":"International prognostic indices in diffuse large B-cell lymphoma: a comparison of IPI, R-IPI, and NCCN-IPI","volume":"135","author":"Ruppert","year":"2020","journal-title":"Blood"},{"key":"B33","doi-asserted-by":"publisher","first-page":"8519","DOI":"10.1200\/jco.2014.32.15_suppl.8519","article-title":"Preliminary results of a phase II randomized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed\/refractory (R\/R) non-Hodgkin lymphoma (NHL)","volume":"32","author":"Morschhauser","year":"2020","journal-title":"J Clin Oncol"},{"key":"B34","unstructured":"targetedonc2020"},{"key":"B35","doi-asserted-by":"publisher","first-page":"879","DOI":"10.1177\/1060028020909117","article-title":"Management of mantle cell lymphoma in the era of novel oral agents","volume":"54","author":"Buege","year":"2020","journal-title":"Ann Pharmacother"},{"key":"B36","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1111\/ejh.13337","article-title":"Outcomes of treatment with dose-adjusted EPOCH-R or R-CHOP in primary mediastinal large B-cell lymphoma","volume":"104","author":"Malenda","year":"2020","journal-title":"Eur J Haematol"},{"key":"B37","unstructured":"SpringerBurkitt Burkitt-Like Lymphomas: A Systematic Review2020"},{"key":"B38","doi-asserted-by":"publisher","first-page":"e1027","DOI":"10.1212\/WNL.0000000000008900","article-title":"Management and outcome of primary CNS lymphoma in the modern era: an LOC network study","volume":"94","author":"Houillier","year":"2020","journal-title":"Neurology"},{"key":"B39","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1002\/hon.2705","article-title":"Survival benefit in patients with peripheral T-cell lymphomas after treatments with novel therapies and clinical trials","volume":"38","author":"Ma","year":"2020","journal-title":"Hematol Oncol"},{"key":"B40","doi-asserted-by":"publisher","first-page":"F1000","DOI":"10.12688\/f1000research.21922.1","article-title":"Recent advances in understanding and managing cutaneous T-cell lymphomas","volume":"9","author":"Brunner","year":"2020","journal-title":"F1000Res"},{"key":"B41","unstructured":"New Treatment Options in Advanced Stage Follicular Lymphoma: HemaSphere2020"},{"key":"B42","doi-asserted-by":"publisher","first-page":"e317","DOI":"10.1097\/HS9.0000000000000317","article-title":"Controversies in the treatment of follicular lymphoma","volume":"4","author":"H\u00fcbel","year":"2020","journal-title":"Hemasphere"},{"key":"B43","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1002\/ajh.25856","article-title":"Hodgkin lymphoma: a 2020 update on diagnosis, risk-stratification, and management","volume":"95","author":"Ansell","year":"2020","journal-title":"Am J Hematol"},{"key":"B44","unstructured":"GHSG - German Hodgkin Study GroupInternational Hodgkin Symposium2020"},{"key":"B45","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1002\/hon.2597","article-title":"Options for first line therapy of Hodgkin lymphoma","volume":"37","author":"Longley","year":"2019","journal-title":"Hematol Oncol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"35","author":"Straus","year":"2020","journal-title":"Blood"},{"key":"B47","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1200\/JCO.2017.75.2543","article-title":"Early chemotherapy intensification with escalated BEACOPP in patients with advanced-stage Hodgkin lymphoma with a positive interim positron emission tomography\/computed tomography scan after two ABVD cycles: long-term results of the GITIL\/FIL HD 0607 trial","volume":"36","author":"Gallamini","year":"2018","journal-title":"J Clin Oncol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"1238","DOI":"10.1182\/blood.2019000719","article-title":"Five-year follow-up of SWOG S0816: limitations and values of a PET-adapted approach with stage III\/IV Hodgkin lymphoma","volume":"134","author":"Stephens","year":"2019","journal-title":"Blood"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.1177\/2040620720902911","article-title":"Optimizing outcomes in relapsed\/refractory Hodgkin lymphoma: a review of current and forthcoming therapeutic strategies","volume":"11","author":"Vassilakopoulos","year":"2020","journal-title":"Ther Adv Hematol"},{"key":"B50","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1038\/s41375-020-0876-z","article-title":"Management of patients with multiple myeloma in the era of COVID-19 pandemic: a consensus paper from the European Myeloma Network (EMN)","volume":"34","author":"Terpos","year":"2020","journal-title":"Leukemia"},{"key":"B51","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.25791","article-title":"Multiple myeloma: 2020 update on diagnosis, risk-stratification and management","volume":"95","author":"Rajkumar","year":"2020","journal-title":"Am J Hematol"},{"key":"B52","doi-asserted-by":"publisher","first-page":"512","DOI":"10.1007\/s12185-020-02841-w","article-title":"Latest treatment strategies aiming for a cure in transplant-eligible multiple myeloma patients: how I cure younger MM patients with lower cost","volume":"111","author":"Suzuki","year":"2020","journal-title":"Int J Hematol"},{"key":"B53","doi-asserted-by":"publisher","first-page":"676","DOI":"10.3389\/fonc.2020.00676","article-title":"The role of immunotherapy in non-transplant eligible multiple myeloma","volume":"10","author":"Bobin","year":"2020","journal-title":"Front Oncol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/ejh.13407","article-title":"Network meta-analysis of first-line treatments in transplant-ineligible multiple myeloma patients","volume":"105","author":"Gil-Sierra","year":"2020","journal-title":"Eur J Haematol"},{"key":"B55","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1182\/blood.2019000722","article-title":"Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"134","author":"Chari","year":"2019","journal-title":"Blood"},{"key":"B56","doi-asserted-by":"publisher","first-page":"2343","DOI":"10.1038\/s41375-019-0561-2","article-title":"Relapsed refractory multiple myeloma: a comprehensive overview","volume":"33","author":"Bazarbachi","year":"2019","journal-title":"Leukemia"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.564383\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,3,15]],"date-time":"2021-03-15T05:59:21Z","timestamp":1615787961000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2021.564383\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,3,15]]},"references-count":56,"alternative-id":["10.3389\/fonc.2021.564383"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2021.564383","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,3,15]]},"article-number":"564383"}}